GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Astellas Pharma Inc (TSE:4503) » Definitions » Cyclically Adjusted Revenue per Share

Astellas Pharma (TSE:4503) Cyclically Adjusted Revenue per Share : 円738.17 (As of Mar. 2024)


View and export this data going back to 1949. Start your Free Trial

What is Astellas Pharma Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Astellas Pharma's adjusted revenue per share for the three months ended in Mar. 2024 was 円230.259. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is 円738.17 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Astellas Pharma's average Cyclically Adjusted Revenue Growth Rate was 7.50% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 7.40% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 6.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Astellas Pharma was 7.40% per year. The lowest was 4.80% per year. And the median was 5.00% per year.

As of today (2024-05-24), Astellas Pharma's current stock price is 円1561.00. Astellas Pharma's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was 円738.17. Astellas Pharma's Cyclically Adjusted PS Ratio of today is 2.11.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Astellas Pharma was 3.80. The lowest was 2.01. And the median was 2.98.


Astellas Pharma Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Astellas Pharma's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Astellas Pharma Cyclically Adjusted Revenue per Share Chart

Astellas Pharma Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 575.25 596.54 629.71 686.96 738.17

Astellas Pharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 686.96 699.80 714.70 726.05 738.17

Competitive Comparison of Astellas Pharma's Cyclically Adjusted Revenue per Share

For the Drug Manufacturers - General subindustry, Astellas Pharma's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Astellas Pharma's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Astellas Pharma's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Astellas Pharma's Cyclically Adjusted PS Ratio falls into.



Astellas Pharma Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Astellas Pharma's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=230.259/107.2000*107.2000
=230.259

Current CPI (Mar. 2024) = 107.2000.

Astellas Pharma Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 132.724 98.000 145.184
201409 135.348 98.500 147.303
201412 162.036 97.900 177.429
201503 133.651 97.900 146.347
201506 156.739 98.400 170.756
201509 158.734 98.500 172.754
201512 175.735 98.100 192.037
201603 143.838 97.900 157.502
201606 158.742 98.100 173.467
201609 147.551 98.000 161.403
201612 167.699 98.400 182.696
201703 146.992 98.100 160.627
201706 156.040 98.500 169.822
201709 154.955 98.800 168.129
201712 178.194 99.400 192.177
201803 150.618 99.200 162.765
201806 166.796 99.200 180.247
201809 164.266 99.900 176.269
201812 186.158 99.700 200.162
201903 158.313 99.700 170.222
201906 177.031 99.800 190.158
201909 167.638 100.100 179.528
201912 180.191 100.500 192.204
202003 167.945 100.300 179.499
202006 165.158 99.900 177.227
202009 165.996 99.900 178.126
202012 175.097 99.300 189.027
202103 166.191 99.900 178.335
202106 175.894 99.500 189.506
202109 175.600 100.100 188.055
202112 183.746 100.100 196.779
202203 165.051 101.100 175.010
202206 209.105 101.800 220.197
202209 208.618 103.100 216.914
202212 220.595 104.100 227.164
202303 193.842 104.400 199.041
202306 208.491 105.200 212.455
202309 217.710 106.200 219.760
202312 234.326 106.800 235.204
202403 230.259 107.200 230.259

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Astellas Pharma  (TSE:4503) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Astellas Pharma's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=1561.00/738.17
=2.11

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Astellas Pharma was 3.80. The lowest was 2.01. And the median was 2.98.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Astellas Pharma Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Astellas Pharma's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Astellas Pharma (TSE:4503) Business Description

Industry
Traded in Other Exchanges
Address
2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo, JPN, 103-8411
Astellas Pharma Inc is a drug manufacturing company that sells pharmaceutical products across the globe. The vast majority of the company's revenue is derived from Japanese markets, followed by the Americas. Royalty income makes up a small percentage of Astellas' overall sales. Its largest therapeutic area by sales composition is oncology, followed by urology and transplantation. The company uses mergers and acquisitions as part of its long-term growth strategy. Astellas enters into strategic partnerships and licensing agreements to strengthen its commercialization platforms.

Astellas Pharma (TSE:4503) Headlines

No Headlines